+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Adult Vaccine Market, Global Analysis By Disease (Influenza, Cervical Cancer, Zoster, MMR , Pneumonia, Meningitis, Hepatitis, Tap , Varicella & Travel & Miscellaneous Vaccine) & Companies

  • ID: 4590297
  • Report
  • July 2018
  • Region: Global
  • 218 Pages
  • Renub Research
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now
The Adult Vaccine Market is Projected to Reach US$ 22 Billion by 2024

FEATURED COMPANIES

  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sanofi
  • MORE

Adult Vaccine Market is projected to reach US$ 22 Billion by the year 2024. Vaccination can help prevent certain diseases in all the people. Nearly all countries across the globe have introduced a well-organized National immunization Programs in their vaccination schedule to overcome the outbreak of vaccine-preventable diseases. Several organizations such as Global Immunization Vision and Strategy (GIVS), WHO’s Global Vaccine Action Plan, The GAVI Alliance are putting their best to reduce the occurrence of vaccine-preventable diseases around the world which certainly is driving the adult vaccine market sturdily.

Rising prevalence of diseases, growing awareness among the people regarding vaccine-preventable diseases, increasing investments by companies to develop new vaccines and increasing governments and other healthcare authorities (Bill & Melinda Gates Foundation) funding for promoting immunization programs as well as for the developments & distribution of the vaccines are some other key factors which are anticipated to augment the growth of global adult vaccine during the forecast period.

This report titled “Adult Vaccine Market, Global Analysis By Disease [Influenza, Cervical Cancer, Zoster (Shingles), MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Varicella and Travel & Miscellaneous Vaccine], Companies (GlaxoSmithKline, Merck, Sanofi, Pfizer, & Others)” provides a complete analysis of Global Adults Vaccine Market.

By Disease - Pneumococcal Vaccine is likely to grow at a noteworthy rate over the coming years

The report studies the market of the following vaccine: Influenza, Cervical Cancer, Zoster (Shingles), MMR (Measles, Mumps, and Rubella), Pneumonia, Meningitis, Hepatitis, Tap (Diphtheria, Tetanus, Pertussis), Varicella, and Travel & Miscellaneous Vaccine. Pneumococcal and Hepatitis together hold the significant market share in the global adult vaccine market and is expected to continue so in the forecast period.

By End User - Global Adults Vaccine Market

The report studies the market by the end user as Adults. Around the world, thousands of adults become seriously ill, get hospitalized and even die because of diseases that vaccines can help prevent. By getting vaccinated, one can help protect themselves from much of this needless suffering.

Almost 350 Million Adults get vaccinated by 2024

Due to the increasing prevalence of diseases and growing awareness regarding the vaccine-preventable diseases, it is estimated that by the year 2024, nearly 350 million adults get vaccinated; in order to protect themselves from diseases. Some of the vaccines which hold a considerable share in terms of adult vaccination include Influenza, Hepatitis, HPV and Pneumonia vaccine.

Regional - Immunization Profile

The report also studies the Immunization profile around the world; By Disease - Measles, Mumps, Rubella, Japanese encephalitis, Tetanus, Pertussis, Yellow Fever. While By Regions, it studies Americas (AMR), Europe (EUR), Africa (AFR), Eastern Mediterranean (EMR), South-East Asia (SEAR), Western Pacific (WPR) and Global.

Company Analysis:

GlaxoSmithKline, Merck, Sanofi, and Pfizer are some of the top companies that deal efficiently with vaccine business globally. These companies have been studied thoroughly in the report.

Global Adults Vaccine Market has been extensively studied from 3 major points:

1. Adult Vaccines (Disease wise) Market & Forecast
2. Number of Vaccinated Adults (Disease wise) & Forecast
3. Doses of Vaccines Administered in Adults(Disease wise) & Forecast

By Disease:

  • Influenza
  • Cervical Cancer
  • Zoster (Shingles)
  • MMR (Measles, Mumps, and Rubella)
  • Pneumonia
  • Meningitis
  • Hepatitis
  • Tap (Diphtheria, Tetanus, Pertussis)
  • Varicella
  • Travel & Miscellaneous Vaccine

Key Companies Covered in the Report:

  • GlaxoSmithKline
  • Merck
  • Sanofi
  • Pfizer
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sanofi
  • MORE

1. Research Findings

2. Adult Vaccines Market (2011 - 2024)

3. Market & Numbers Share - Adult Vaccines
3.1 Adult Vaccine Market Share
3.2 Adult Vaccinated Population Share
3.3 Adult Doses of Vaccines Administered Share
3.4 Vaccine Companies Market Share

4. Adult Vaccinated Numbers

5. Adult Doses of Vaccines Administered

6. Disease wise - Adult Vaccines Market (2011 - 2024)
6.1 Influenza
6.2 Cervical Cancer (HPV)
6.3 Zoster (Shingles)
6.4 MMR (Measles, Mumps, and Rubella Vaccine)
6.5 Pneumococcal
6.6 Meningococcal
6.7 Hepatitis
6.8 TdaP
6.9 Travel and Miscellaneous
6.10 Varicella

7. Disease wise - Numbers of Vaccinated Adults (2011 - 2024)
7.1 Influenza
7.2 Cervical Cancer (HPV)
7.3 Zoster (Shingles)
7.4 MMR
7.5 Pneumococcal
7.6 Meningococcal
7.7 Hepatitis
7.8 TdaP
7.9 Varicella

8. Disease wise - Doses of Vaccines Administered in Adults (2011 - 2024)
8.1 Influenza
8.2 Cervical Cancer (HPV)
8.3 Zoster (Shingles)
8.4 MMR
8.5 Pneumococcal
8.6 Meningococcal
8.7 Hepatitis
8.8 TdaP
8.9 Varicella

9. Disease wise - Immunization Profile
9.1 Immunization Coverage (%) in Infants
9.2 Global Immunization Profile
9.3 By Geographic Region - Immunization Profile
9.3.1 Measles - Number of Reported Cases
9.3.2 Mumps - Number of Reported Cases
9.3.3 Rubella - Number of Reported Cases
9.3.4 Rubella (CRS) - Number of Reported Cases
9.3.5 Diphtheria - Number of Reported Cases
9.3.6 Tetanus (Neonatal) - Number of Reported Cases
9.3.7 Tetanus (Total) - Number of Reported Cases
9.3.8 Pertussis - Number of Reported Cases
9.3.9 Polio - Number of Reported Cases
9.3.10 Yellow Fever - Number of Reported Cases
9.3.11 Japanese encephalitis - Number of Reported Cases

10. Vaccines Key Players Sales (2011 - 2024)
10.1 GlaxoSmithKline, plc.’s Vaccines Sales
10.2 Merck & Co. Vaccines Sales
10.3 Sanofi Pasteur’s Vaccines Sales
10.4 Pfizer, Inc.’s Vaccines Sales
10.5 Global - Other Companies Vaccines Sales

11. Vaccines - Products and Pipeline
11.1 GSK Vaccine Product Pipeline
11.2 Merck Vaccine Product Pipeline
11.3 Sanofi Vaccine Product Pipeline
11.4 Pfizer Vaccine Product Pipeline

12. Top Mergers and Acquisitions in the Vaccine Industry

13. Vaccines and Regulator’s Interventions
13.1 Making and Meeting Standards of Quality and Safety
13.2 Vaccine Funding

14. Vaccine Market Drivers
14.1 Inclusion in National Immunization Schedule
14.2 Growing Immunization Coverage for HPV Vaccines
14.3 Increase in Prevalence of Infectious Diseases
14.4 Global Immunization Vision and Strategy (GIVS)
14.5 GAVI Model Fuelling Vaccine Manufacturers
14.5.1 The Partnership Model
14.5.2 The Business Model
14.6 Increasing Vaccine Availability in the United States
14.7 The Vaccine Safety Data link Project
14.8 The Vaccine Injury Compensation Program
14.9 Transforming of Vaccine Technologies
14.10 Global Vaccine Action Plan by WHO (2011 - 2020)
14.11 Continuous Focus on Effective Communication Strategies

15. Vaccines Market Challenges
15.1 Hurdles to Optimal use of Licensed Vaccines
15.1.1 Technical Obstacles
15.1.2 Economic Obstacles
15.1.3 Cultural Obstacles
15.2 Complexity of Vaccine Development & Approval System Thwarts Product Development
15.2.1 Legal Obstacles
15.2.2 General Technical Barriers
15.2.3 Economic Barriers
15.2.4 Regulatory Barriers
15.3 Shortening the Timeline for Vaccine Development
15.4 Refusal/Resistance to Vaccination
15.4.1 Vaccine Adverse Event Reporting System
15.5 Vaccine Shortages and Delays
15.6 Obstacles in Vaccine Research & Development
15.7 Barriers to New Entrants in the Vaccines Market

List of Figures
Figure 2-1: Global - Adult Vaccines Market (Billion US$), 2011 - 2017
Figure 2-2: Global - Forecast for Adult Vaccines Market (Billion US$), 2018 - 2024
Figure 3-1: Global - Adult Vaccines Market Share (Percent), 2011 - 2017
Figure 3-2: Global - Forecast for Adult Vaccines Market Share (Percent), 2018 - 2024
Figure 3-3: Global - Vaccinated Adult Share (Percent), 2011 - 2017
Figure 3-4: Global - Forecast for Vaccinated Adult Share (Percent), 2018 - 2024
Figure 3-5: Global - Doses of Vaccines Administered to Adult Share (Percent), 2011 - 2017
Figure 3-6: Global - Forecast for Doses of Vaccines Administered to Adult Share (Percent), 2018 - 2024
Figure 3-7: Global - Key Players Vaccines Market Share (Percent), 2011 - 2017
Figure 3-8: Global - Forecast for Key Players Vaccines Market Share (Percent), 2018 - 2024
Figure 4-1: Global - Number of Vaccinated Adult (Million), 2011 - 2017
Figure 4-2: Global - Forecast for Number of Vaccinated Adult (Million), 2018 - 2024
Figure 5-1: Global - Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 5-2: Global - Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 6-1: Influenza - Adult Vaccines Market (Billion US$), 2011 - 2017
Figure 6-2: Influenza - Forecast for Adult Vaccines Market (Billion US$), 2018 - 2024
Figure 6-3: Cervical Cancer (HPV) - Vaccines Market (Billion US$), 2011 - 2017
Figure 6-4: Cervical Cancer (HPV) - Forecast for Vaccines Market (Billion US$), 2018 - 2024
Figure 6-5: Zoster (Shingles) - Vaccines Market (Billion US$), 2011 - 2017
Figure 6-6: Zoster (Shingles) - Forecast for Vaccines Market (Billion US$), 2018 - 2024
Figure 6-7: MMR - Adult Vaccines Market (Million US$), 2011 - 2017
Figure 6-8: MMR - Forecast for Adult Vaccines Market (Million US$), 2018 - 2024
Figure 6-9: Pneumococcal - Adult Vaccines Market (Billion US$), 2011 - 2017
Figure 6-10: Pneumococcal - Forecast for Adult Vaccines Market (Billion US$), 2018 - 2024
Figure 6-11: Areas with frequent epidemics of meningococcal meningitis
Figure 6-12: Meningococcal - Adult Vaccines Market (Million US$), 2011 - 2017
Figure 6-13: Meningococcal - Forecast for Adult Vaccines Market (Million US$), 2018 - 2024
Figure 6-14: Hepatitis - Adult Vaccines Market (Billion US$), 2011 - 2017
Figure 6-15: Hepatitis - Forecast for Adult Vaccines Market (Billion US$), 2018 - 2024
Figure 6-16: TdaP - Adult Vaccines Market (Million US$), 2011 - 2017
Figure 6-17: TdaP - Forecast for Adult Vaccines Market (Million US$), 2018 - 2024
Figure 6-18: Travel and Miscellaneous - Vaccines Market (Billion US$), 2011 - 2017
Figure 6-19: Travel and Miscellaneous - Forecast for Vaccines Market (Billion US$), 2018 - 2024
Figure 6-20: Varicella - Adult Vaccines Market (Million US$), 2011 - 2017
Figure 6-21: Varicella - Forecast for Adult Vaccines Market (Million US$), 2018 - 2024
Figure 7-1: Influenza - Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-2: Influenza - Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 7-3: Cervical Cancer - Number of Vaccinated People (Million), 2011 - 2017
Figure 7-4: Cervical Cancer - Forecast for Number of Vaccinated People (Million), 2018 - 2024
Figure 7-5: Zoster (Shingles) - Number of Vaccinated People (Million), 2011 - 2017
Figure 7-6: Zoster (Shingles) - Forecast for Number of Vaccinated People (Million), 2018 - 2024
Figure 7-7: MMR - Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-8: MMR - Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 7-9: Pneumococcal - Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-10: Pneumococcal - Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 7-11: Meningococcal - Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-12: Meningococcal - Forecast for Number of Vaccinated Adults (Million), 2018 - 2024
Figure 7-13: Hepatitis - Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-14: Hepatitis - Forecast for Number of Adults Immunized (Thousand), 2018 - 2024
Figure 7-15: TdaP - Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-16: TdaP - Number of Vaccinated Adults (Million), 2018 - 2024
Figure 7-17: Varicella - Number of Vaccinated Adults (Million), 2011 - 2017
Figure 7-18: Varicella - Number of Vaccinated Adults (Million), 2018 - 2024
Figure 8-1: Influenza - Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-2: Influenza - Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 8-3: Cervical Cancer (HPV) - Doses of Vaccines Administered (Million), 2011 - 2017
Figure 8-4: Cervical Cancer (HPV) - Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 8-5: Zoster (Shingles) - Doses of Vaccines Administered (Million), 2011 - 2017
Figure 8-6: Zoster (Shingles) - Forecast for Doses of Vaccines Administered (Million), 2018 - 2024
Figure 8-7: MMR - Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-8: MMR - Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 8-9: Pneumococcal - Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-10: Pneumococcal - Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 8-11: Meningococcal - Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-12: Meningococcal - Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 8-13: Hepatitis - Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-14: Hepatitis - Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 8-15: TdaP - Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-16: TdaP - Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 8-17: Varicella - Doses of Adult Vaccines Administered (Million), 2011 - 2017
Figure 8-18: Varicella - Forecast for Doses of Adult Vaccines Administered (Million), 2018 - 2024
Figure 10-1: Global - GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-2: Global - Forecast for GlaxoSmithKline, plc.’s Vaccines Sales (Billion US$), 2018 - 2024
Figure 10-3: Global - Merck & Co. Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-4: Global - Forecast for Merck & Co. Vaccines Sales (Billion US$), 2018 - 2024
Figure 10-5: Global - Sanofi Pasteur’s Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-6: Global - Forecast for Sanofi Pasteur’s Vaccines Sales (Billion US$), 2018 - 2024
Figure 10-7: Global - Pfizer, Inc.’s Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-8: Global - Forecast for Pfizer, Inc.’s Vaccines Sales (Billion US$), 2018 - 2024
Figure 10-9: Global - Other Companies Vaccines Sales (Billion US$), 2011 - 2017
Figure 10-10: Global - Forecast for Other Companies Vaccines Sales (Billion US$), 2018 - 2024
Figure 11-1: GSK Vaccine Product Pipeline
Figure 14-1: Countries with HPV Vaccination Program listed on their National Immunization Program (NIP) Schedule
Figure 14-2: Number of Cases of Diphtheria, Pertussis, Tetnaus & Measles by Major Region Worldwide, 2013
Figure 14-3: Vaccines Procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 14-4: Vaccines procured by UNICEF: Industrialized and Emerging Market Country Manufacturers
Figure 14-5: US Retail Clinics Expected to Surge by 2017

Lists of Tables
Table 2-1: Vaccine Recommendations
Table 2-2: Other Recommended Vaccines
Table 9-1: Worldwide Immunization Coverage (%) in Infants, 2005- 2010
Table 9-2: Worldwide Immunization Coverage (%) in Infants, 2011- 2016
Table 9-3: Vaccines - Number of Reported Cases, 2011 - 2017
Table 9-4: Measles - Number of Reported Cases, 2001 - 2016
Table 9-5: Mumps - Number of Reported Cases, 2001 - 2016
Table 9-6: Rubella - Number of Reported Cases, 2001 - 2016
Table 9-7: Rubella (CRS) - Number of Reported Cases, 2001 - 2016
Table 9-8: Diphtheria - Number of Reported Cases, 2001 - 2016
Table 9-9: Tetanus (Neonatal) - Number of Reported Cases, 2001 - 2016
Table 9-10: Tetanus (Total) - Number of Reported Cases, 2001 - 2016
Table 9-11: Pertussis - Number of Reported Cases, 2001 - 2016
Table 9-12: Polio - Number of Reported Cases, 2001 - 2016
Table 9-13: Yellow Fever - Number of Reported Cases, 2001 - 2016
Table 9-14: Japanese Encephalitis - Number of Reported Cases Reported, 2006 - 2016
Table 11-1: Merck Vaccine Product Pipeline
Table 11-2: Sanofi Vaccine Product Pipeline
Table 11-3: Pfizer Vaccine Product Pipeline
Table 12-1: Vaccine Mergers & Acquisitions
Table 14-1: United States Immunization Schedule
Table 14-2: Afghanistan Immunization Schedule
Table 14-3: Norway Immunization Schedule
Table 14-4: India Immunization Schedule
Table 14-5: Vietnam Immunization Schedule
Table 14-6: Worldwide - Total Future Deaths Averted through Vaccination (Million), 2011 - 2020
Table 14-7: Goal-Level Indicators, 2015 & 2020
Table 14-8: Improvement Strategies or Requirements - the Joint Commission and the Project’s Collaborating Organizations

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • GlaxoSmithKline
  • Merck
  • Pfizer
  • Sanofi
Note: Product cover images may vary from those shown
5 of 4

In this report, for analyzing the future trends for the studied market during the forecast period, the publisher has incorporated rigorous statistical and econometric methods, further scrutinized by secondary, primary sources and by in-house experts, supported through their extensive data intelligence repository. The market is studied holistically from both demand and supply-side perspectives. This is carried out to analyze both end-user and producer behavior patterns, in the review period, which affects price, demand and consumption trends. As the study demands to analyze the long-term nature of the market, the identification of factors influencing the market is based on the fundamentality of the study market.

Through secondary and primary researches, which largely include interviews with industry participants, reliable statistics, and regional intelligence, are identified and are transformed to quantitative data through data extraction, and further applied for inferential purposes. The publisher's in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of their recommendations and advice.

Primary Research

The primary purpose of this phase is to extract qualitative information regarding the market from the key industry leaders. The primary research efforts include reaching out to participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions. The publisher also established professional corporate relations with various companies that allow us greater flexibility for reaching out to industry participants and commentators for interviews and discussions, fulfilling the following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develop the analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth, and forecast

The researcher's primary research interview and discussion panels are typically composed of the most experienced industry members. These participants include, however, are not limited to:

  • Chief executives and VPs of leading corporations specific to the industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investment, and valuation experts
  • Key opinion leaders (KOLs)

Secondary Research

The publisher refers to a broad array of industry sources for their secondary research, which typically includes, however, is not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, webcasts, and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecasts
 

Loading
LOADING...

Adroll
adroll